NuSirt Biopharma to Present at American Diabetes Association's 76th Scientific Sessions

NASHVILLE, Tenn.--()--NuSirt Biopharma, a company dedicated to improving the lives of those with chronic metabolic diseases, will be presenting two posters featuring its technology at the American Diabetes Association’s 76th Scientific Sessions. The annual event dedicated to sharing the latest advancements in diabetes research, care and treatment takes place on June 10-14, 2016, in New Orleans, Louisiana.

The posters will highlight the potential of NuSirt’s technology, which combines leucine, an essential amino acid, with existing pharmaceuticals, to help those with Type 2 diabetes, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Specifically, the company will be sharing the results of its Phase 2A clinical trial that tests its technology combined with low doses of metformin. In addition, NuSirt will present pre-clinical research on its triple-combination therapy of leucine, sildenafil and metformin.

Details of the poster presentations are as follows:

About Diabetes

Diabetes is the seventh leading cause of death in the U.S., and its complications include blindness, kidney failure and peripheral amputation According to the American Diabetes Association, more than 29 million Americans have diabetes, and an additional 86 million Americans age 20 and older have prediabetes.

About Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)

Non-alcoholic fatty liver disease (NAFLD) is a result of fat building up in the liver, preventing the organ’s ability to remove toxins from the blood. It affects up to one-third of the general population. Although there are no known causes for NAFLD, obesity, high cholesterol, diabetes, and high blood pressure are all considered risk factors. Non-alcoholic steatohepatitis (NASH) occurs in 10 to 30 percent of those with NAFLD. It happens when the liver of a person with NAFLD becomes inflamed, causing severe liver cell damage. Over time, this can result in permanent scarring and hardening of the liver. The consequences of NASH include cardiovascular disease, liver cancer, and liver failure.

About NuSirt Biopharma

NuSirt Biopharma, headquartered in Nashville, TN, is dedicated to improving the lives of people living with chronic metabolic diseases. The company has a unique technology platform that uses patented combinations of leucine, an essential amino acid, with existing human medicines to target diseases that may be addressed by activating sirtuin pathways. In pre-clinical studies, these combinations have shown promise in preventing and treating metabolic diseases by enabling new applications for existing pharmaceuticals and enhancing their effectiveness. For more information, please visit www.nusirt.com.

Contacts

For NuSirt Biopharma
Nicole Cottrill, 615-610-0305
nicole.cottrill@dvlseigenthaler.com

Website

Release Summary

NuSirt Biopharma to present new research at the American Diabetes 76th Annual Scientific Sessions

NuSirt Biopharma